Loading
The trial that moved CAR-T ahead of transplant as second-line treatment for early-relapsing large B-cell lymphoma, with a survival benefit.
ZUMA-7, trial NCT03391466 sponsored by Kite and Gilead and published in the New England Journal of Medicine in 2022 with survival results in 2023, moved CAR-T ahead of transplant as second-line treatment for large B-cell lymphoma that is refractory or relapses within twelve months of first-line therapy. It randomised 359 patients to axicabtagene ciloleucel or salvage chemotherapy followed by autologous transplant, met its primary event-free survival endpoint with a large effect and later showed an overall survival benefit, while only about a third of the standard arm ever reached transplant, leading to approval in the second line in April 2022. OnCo links it to lymphoma, CAR-T, autologous transplant, axi-cel, Sattva S. Neelapu, Jason R. Westin, Frederick L. Locke and the manufacturing bottleneck. Whether CAR-T should move into the first line for high-risk patients is the open question.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
359 enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Event-free survival (median)primary | Axi-cel | 180 | 8.3 months | 0.4 (0.31 to 0.51) | <0.001 | link |
| Standard care | 179 | 2 months | ||||
| Overall survival at 4 years | Axi-cel | - | 54.6% | 0.73 (0.54 to 0.98) | 0.03 | link |
| Standard care | - | 46% |
The reason second-line CAR-T is offered with axicabtagene ciloleucel or lisocabtagene maraleucel rather than tisagenlecleucel. The trial is also the strongest evidence in the field that the interval between apheresis and infusion, and what is given during it, is part of the treatment rather than logistics around it.
TRANSFORM confirmed ZUMA-7's conclusion with a different CD19 CAR-T and a more permissive design that allowed bridging chemotherapy, making the results closer to real-world practice. Liso-cel's low toxicity makes it attractive for older or frailer patients and for outpatient delivery. Together the two trials made CAR-T the standard second-line therapy for early-relapsing aggressive lymphoma.
ZUMA-7 rewrote second-line treatment for aggressive lymphoma: patients whose disease returns within a year of R-CHOP should be offered CAR-T rather than salvage chemotherapy and transplant. It is also one of the few cell-therapy trials to show an overall survival benefit despite crossover. Patients relapsing later than 12 months were not studied and transplant remains standard for them if chemosensitive.
ZUMA-1 showed that CAR-T can cure a meaningful fraction of adults whose aggressive lymphoma no longer responds to chemotherapy, a group with a historical median survival of about six months (SCHOLAR-1). Axi-cel became the first CAR-T approved for lymphoma and later the first to beat standard second-line therapy in ZUMA-7. The comparatively high neurotoxicity of CD28-costimulated products was also first characterised here.
Shares Early relapse: CAR-T before transplant, Transplant or CAR-T at second line in diffuse large B-cell lymphoma, Lymphoma treatments that did not work: the negative trials worth knowing, Salvage therapy.
Shares Sattva S. Neelapu, Non-viral CAR-T (transposon or CRISPR knock-in) as the default manufacturing route, In vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma, JULIET.
Shares TRANSFORM: liso-cel CAR-T versus salvage chemotherapy and transplant in early-relapsing large B-cell lymphoma, Report the time from apheresis to infusion as a trial endpoint, not a logistics footnote, TRANSCEND NHL 001, ZUMA-1: axicabtagene ciloleucel for refractory large B-cell lymphoma, the first CAR-T approved for lymphoma.
Shares BELINDA, JULIET, ZUMA-1: axicabtagene ciloleucel for refractory large B-cell lymphoma, the first CAR-T approved for lymphoma, Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma.
Shares Transplant or CAR-T at second line in diffuse large B-cell lymphoma, TRANSFORM: liso-cel CAR-T versus salvage chemotherapy and transplant in early-relapsing large B-cell lymphoma, JULIET, TRANSCEND NHL 001.
Shares TRANSFORM: liso-cel CAR-T versus salvage chemotherapy and transplant in early-relapsing large B-cell lymphoma, Report the time from apheresis to infusion as a trial endpoint, not a logistics footnote, TRANSCEND NHL 001, The CAR-T pathway in lymphoma: referral, apheresis, bridging and the waiting.
Shares Bridging therapy, Report the time from apheresis to infusion as a trial endpoint, not a logistics footnote, JULIET, The CAR-T pathway in lymphoma: referral, apheresis, bridging and the waiting.
Shares Lymphoma treatments that did not work: the negative trials worth knowing, Report the time from apheresis to infusion as a trial endpoint, not a logistics footnote, JULIET, Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma.